Healthcare Industry News: benign prostatic hyperplasia
News Release - January 10, 2006
Nymox Provides Update on Progress of the Company's Current Drug Trial of NX-1207 for Benign Prostatic HyperplasiaHASBROUCK HEIGHTS, N.J.--(HSMN NewsFeed)--Jan. 10, 2006--Nymox Pharmaceutical Corporation (NASDAQ:NYMX ) today provided an update on the progress of its ongoing multi-center Phase 2 trial of NX-1207, the Company's novel drug treatment for benign prostatic hyperplasia (BPH). The trial is occurring at 35 U.S. sites and is nearing completion. An independent Data Monitoring Committee (DMC) will shortly make its recommendations to the Company, based on efficacy and safety data from the trial. Nymox expects to report on the independent DMC recommendations in the near future. The Company has previously provided internal safety review updates which have shown that there have been no significant safety issues thus far with NX-1207 in the trial.
In the earlier completed Phase 1-2 trials to date, the subjects treated with NX-1207 showed statistically significant overall mean symptom improvement and shrinkage in prostate size. In the initial trials, subjects showed an average 23.4% size reduction in the prostate after one month. There were also no serious adverse events from the drug in the earlier trials. From the earlier completed trials, subjects that were followed for up to two years post-treatment showed major benefit from the drug.
NX-1207 is Nymox's lead drug candidate for the treatment of benign prostatic hyperplasia (BPH) which the company believes shows good promise to greatly improve the available treatment of BPH. In the two previously completed trials in the U.S., the drug has shown excellent efficacy without serious side effects. BPH afflicts approximately half of men over age 50 and close to 90% of men by age 80. The disorder causes difficulties with urination associated with aging, such as urination at night, urge to void frequently, hesitancy, weak stream, and other problems.
More information about Nymox is available at www.nymox.com, email: firstname.lastname@example.org, or 800-936-9669.
This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. The conduct of clinical trials and the development of drug products involve substantial risks and uncertainties and actual results may differ materially from expectations. Promising early results do not ensure that later stage or larger scale clinical trials will be successful or will proceed as expected. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.
Source: Nymox Pharmaceutical
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.